



# **News Release**

## **NORGINE PRESENTATIONS AT DDW 2004**

Norgine is pleased to announce that members of its Research Division and their scientific collaborators will be making a number of presentations at the forthcoming Digestive Diseases Week conference, being held in New Orleans from May 15-20.

The presentations are as follows:

“Results of a randomised, multi-centre, single-blind trial to compare the efficacy, acceptability and safety of a new 2-litre gut cleansing solution versus a standard 4-litre PEG+E solution” – H-J.Gruss (ASGE Poster Session – Preparation, sedation, general endoscopy, May 16<sup>th</sup>)

“A new 2 litre gut lavage solution : Results of a prospective randomised multi-centre controlled trial comparing a PEG + Ascorbic acid solution verses a sodium phosphate solution” – N.Barras, H-J.Gruss, J.Thompson (ASGE Poster Session – Preparation, sedation, general endoscopy, May 16<sup>th</sup>)

“Application of L-erythro methoxamine gel increases anal resting pressure in healthy volunteers” – M.Halphen, N.Barras, H-J Gruss (AGA Poster Session – Anorectal Motility and Disorders, May 17<sup>th</sup>)

“Cholyl-lysyl-fluorescein (CLF) clearance discriminates between healthy volunteers and patient with liver cirrhosis in functional liver assessment” – H-J.Gruss, M.Halphen (AGA Research Forum – Frequency, Function and Outcome in Hepatitis and Cirrhosis, 9.00am, May 18<sup>th</sup>)

“A meta-analysis of the clinical efficacy and safety of a new class of laxatives containing high molecular weight polyethylene glycol in patients with chronic constipation” – M.Halphen, C.Dugue (AGA Poster Session – Pharmacotherapeutics in Functional GI Disorders, 8.00am May 19<sup>th</sup>)

Norgine is a European specialty pharmaceutical company with a direct presence throughout Western Europe. The company revenues reached €133 million in 2003, an increase of 12%, the seventeenth consecutive year of double digit growth. Norgine's activities span from research and development through manufacturing to a sales and marketing team including over 300 medical representatives. Norgine is developing a pipeline of innovative pharmaceutical products addressing serious unmet medical needs with a focus on gastroenterology, hepatology and pain management. Additional information about Norgine can be found at [www.norgine.com](http://www.norgine.com).

- ends -

For further information, please contact : Paul Pay  
Business Development Director  
Norgine International Limited  
Keaton House  
Widewater Place  
Moorhall Road  
Harefield  
Middx UB9 6NS  
UK  
Tel: +44 1895 453710  
E-mail: [ppay@norgine.com](mailto:ppay@norgine.com)

Date: 29<sup>th</sup> April 2004